drugset / Trial / NCT04163432
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.
Timeline
- Start
- 2020-06-16
- Primary completion
- 2025-02-04
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Durvalumab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Pemetrexed | Small molecule | 400 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |